Cara Therapeutics announces offering of 4.5M shares of common stockCara Therapeutics announced that it has commenced an underwritten public offering of 4.5M shares of its common stock. Cara Therapeutics intends to use the net proceeds from the underwritten offering to fund its clinical and research development activities, including the completion of its Phase 3 program and submission of a new drug application to the FDA for Korsuva Injection for the treatment of pruritus associated with chronic kidney disease in hemodialysis patients, the advancement of Oral Korsuva into Phase 2 trials for the treatment of pruritus associated with CKD in Stage III-V patients and chronic liver disease patients, the expansion of its Oral program into certain dermatologic conditions and the exploration of further development of CR845/difelikefalin injection in the post-operative setting after consultation with the FDA, as well as for working capital and other general corporate purposes. Jefferies and BofA Merrill Lynch are acting as lead joint book-running managers for the offering. Piper Jaffray and Stifel are also acting as book-runners for the offering. Canaccord Genuity, Needham, H.C. Wainwright and Janney Montgomery Scott are acting as co-managers for the offering.Read more at: https://thefly.com/landingPage...(Source theFly) * This stock has been on our trading list for a while now. Will continue to look for trades in this name.We look at this as an opportunity to pick up some cheaper shares as the stock is lower after-hours on the news. $CARA, Cara Therapeutics, Inc. / M30 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.